Chardan Capital Reiterates “Buy” Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at Chardan Capital in a research report issued on Tuesday,Benzinga reports. They presently have a $60.00 price target on the biotechnology company’s stock. Chardan Capital’s target price would indicate a potential upside of 223.10% from the company’s current price. […]